Earnings summaries and quarterly performance for SURMODICS.
Research analysts who have asked questions during SURMODICS earnings calls.
James Sidoti
Sidoti & Company
4 questions for SRDX
Also covers: ANIK, ASRT, GAIA +10 more
MP
Michael Petusky
Barrington Research
3 questions for SRDX
Also covers: ANIK, HAE, HSIC +8 more
BO
Brooks O'Neil
Lake Street Capital Markets
2 questions for SRDX
Also covers: ARAY, ATEC, BBNX +11 more
Joseph Conway
Needham & Company, LLC
2 questions for SRDX
Also covers: AORT, ATRC, ENOV +6 more
Michael Matson
Needham & Company
2 questions for SRDX
Also covers: AORT, ATRC, CNMD +22 more
Mike Matson
Needham & Company, LLC
1 question for SRDX
Also covers: CNMD, ENOV, ESTA +16 more
Recent press releases and 8-K filings for SRDX.
Surmodics Acquisition by GTCR Cleared by US Court
SRDX
M&A
Legal Proceedings
Takeover Bid
- A federal judge denied the FTC's request for a preliminary injunction, allowing GTCR's $627 million acquisition of Surmodics to proceed despite regulatory challenges over competition concerns in the hydrophilic coatings market.
- The court ruled that GTCR and Surmodics successfully rebutted the presumption that the transaction would substantially lessen competition.
- To address antitrust concerns, GTCR agreed to divest certain assets, including key employees, a factory, and Biocoat contracts, to Integer Holdings Corp for up to $15 million.
- The deal, valued at $43 per share, can now move forward, though a temporary restraining order delays finalization until November 17, pending the FTC's administrative trial.
- Surmodics' stock price, which initially rallied to $42.36 after the acquisition announcement, has since fallen more than 30% during the legal challenges, closing at $27.34 following the court ruling.
Nov 11, 2025, 1:05 AM
Surmodics Reports Q2 2025 Results and Issues FY 2025 Guidance
SRDX
Guidance Update
Product Launch
M&A
- Q2 2025 results: Reported total revenue of $28.1 million, a GAAP loss of $(5.2) million, and Adjusted EBITDA of $1.9 million, driven by declines in SurVeil DCB revenue and product sales.
- Fiscal 2025 guidance: Expects total revenue between $114 million and $117 million (or $112.5 million to $115.5 million excluding SurVeil DCB license fees) with GAAP net loss per diluted share projected between $(1.60) and $(1.40).
- Strategic updates: Announced the commercial launch of the Pounce XL Thrombectomy System and noted ongoing progress related to the pending acquisition by GTCR amid FTC litigation.
Apr 30, 2025, 12:00 AM
Quarterly earnings call transcripts for SURMODICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more